By Christy Santhosh Feb 23 (Reuters) - Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its ...
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...
Gilead has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval.
The inaugural direct-to-consumer campaign for the injectable drug debuted earlier this year, centering around a TV ad featuring a remake of Ciara and Missy Elliott’s 2004 hit song “1, 2 Step”—now ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...
At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.
The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...
Biotech heavyweight Gilead Sciences is set to acquire a Rockville-area cancer therapy developer in a deal valued at nearly $8 billion.
Merck's blockbuster immunotherapy Keytruda, which generates nearly half of its total revenue, is scheduled to lose U.S. patent protection in 2028, opening the door to lower-cost generic competition.
Feb 23 (Reuters) - Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results